We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




CD Diagnostics Acquires CLIA-Accredited Citrano Medical Laboratories

By LabMedica International staff writers
Posted on 30 Oct 2012
CD Diagnostics, Inc. More...
(Wynnewood, PA, USA) completed the purchase of 80% of the outstanding capital stock of Citrano Medical Laboratories, Inc. (CML; Towson, MD, USA).

CML provides clinical laboratory testing to physicians, clinics, and long-term care facilities. The combination of Citrano with CD Diagnostics creates an entity with both a strong R and D team that can produce Laboratory Developed Tests (LDTs), and a Clinical Laboratory Improvement Amendments (CLIA)-certified diagnostics laboratory dedicated to customer service in which these tests can be run.

CD Diagnostics' immunoassays use a small sample of a patient’s joint fluid (synovial fluid) to measure the presence of proteins or biomarkers that are produced by the body and are specific to a particular joint disease. The presence of these biomarkers in elevated levels indicates that the patient is reacting to a specific joint disease and serves as a positive diagnosis. Results are accurate and available within five to ten minutes. The first test, an immunoassay to diagnose infection in joint replacements, is planned for release in November 2012. Joint infection is a very serious condition that must be ruled out with any joint disease.

The first test, CD Diagnostics’ new synovial fluid assays will enhance Citrano’s portfolio of testing services, which currently include hematology, urinalysis, and a broad range of other services.

The acquisition of Citrano is one of the milestones achieved by CD Diagnostics since its incorporation in December 2011. In June 2012, the company signed a commercialization agreement with an orthopedic company for the development of its infection test, receiving USD 2.9 million in milestone payments.

Richard Birkmeyer, CEO of CD Diagnostics, commented, “When you have inflammation in a joint, it can be a wide range of causes such as Lyme disease, gout, bacterial infection. Our test tells exactly what is causing that pain, no matter what the joint.” Tests for other joint diseases are in development.

Related Links:

CD Diagnostics, Inc.
Citrano Medical Laboratories, Inc.



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated PCR Setup
ESTREAM
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: Brain biomarkers of Alzheimer\'s disease can be detected as early as middle age (Photo courtesy of University of Shutterstock)

Blood-Based Biomarkers Could Detect Alzheimer's as Early as Middle Age

As the global population ages, Alzheimer's disease and other dementing diseases are becoming more prevalent. The disease processes leading to Alzheimer's symptoms can begin years or even decades before... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.